REGENERON PHARMACEUTICALS, INC. Deferred Foreign Income Tax Expense (Benefit)
REGENERON PHARMACEUTICALS, INC. (REGN) reported Deferred Foreign Income Tax Expense (Benefit) of $75.30 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-04.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredForeignIncomeTaxExpenseBenefit · last filed 2026-02-04
- REGENERON PHARMACEUTICALS, INC. deferred foreign income tax expense (benefit) for fiscal 2025 was $75.30M, a 58.87% decline from fiscal 2024.
- REGENERON PHARMACEUTICALS, INC. deferred foreign income tax expense (benefit) for fiscal 2024 was $183.10M, a 5621.88% increase from fiscal 2023.
- REGENERON PHARMACEUTICALS, INC. deferred foreign income tax expense (benefit) for fiscal 2023 was $3.20M, a 94.07% decline from fiscal 2022.
- REGENERON PHARMACEUTICALS, INC. deferred foreign income tax expense (benefit) for fiscal 2022 was $54.00M, a 80.48% decline from fiscal 2021.
| Period end | Deferred Foreign Income Tax Expense (Benefit) 12 month | Deferred Foreign Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | $75.30M 10-K · filed 2026-02-04 | |
| 2024-12-31 | $183.10M 10-K · filed 2026-02-04 | |
| 2023-12-31 | $3.20M 10-K · filed 2026-02-04 | |
| 2022-12-31 | $54.00M 10-K · filed 2025-02-05 | |
| 2021-12-31 | $276.70M 10-K · filed 2024-02-05 | |
| 2020-12-31 | -$31.40M 10-K · filed 2023-02-06 | |
| 2019-12-31 | $3.10M 10-K · filed 2022-02-07 | |
| 2018-12-31 | -$825.70M 10-K · filed 2021-02-08 | |
| 2017-12-31 | $3.20M 10-K · filed 2020-02-07 | $3.20M 10-K · filed 2018-02-08 |
| 2016-12-31 | $3.90M 10-K · filed 2019-02-07 | $3.86M 10-K · filed 2017-02-09 |
| 2015-12-31 | -$6.47M 10-K · filed 2018-02-08 | |
| 2014-12-31 | -$1.49M 10-K · filed 2017-02-09 | |
| 2013-12-31 | -$9.00K 10-K · filed 2016-02-11 | |
| 2012-12-31 | $0.00 10-K · filed 2015-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |